- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06496750
Ketamin för metamfetaminanvändningsstörning (KMD)
NIDA CTN-0132 Randomiserad, dubbelblind, aktiv placebokontrollerad prövning av ketamin mot metamfetaminanvändningsstörning (KMD)
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.
The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Effective management for methamphetamine use disorder (MUD) remains elusive, despite widespread misuse of this stimulant. Psychological interventions have demonstrated modest benefits, and relapse rates are high. There are currently no Food and Drug Administration (FDA)-approved pharmacotherapies for MUD. This study explores the efficacy, safety, and feasibility for intravenous (IV) ketamine as a treatment for MUD and will help to determine the effect size for a larger, multi-site trial of intravenous (IV) ketamine in MUD.
Participants will receive either IV ketamine (0.50mg/kg) or IV midazolam (0.02mg/kg) over 45 minutes per infusion for a total of eight (8) infusions over six (6) weeks. Medical management sessions with a study clinician will be provided to all participants once weekly (from Weeks 1 through 6).
The use of IV ketamine in this trial is consistent in dose (0.5 mg/kg) and duration of infusion (45-minute-long) to other studies of ketamine for psychiatric disorders (such as major depressive disorder and post-traumatic stress disorder, both of which are often comorbid in individuals with MUD) and substance use disorder. However, IV ketamine has not been directly evaluated as mono-pharmacotherapy in those with MUD yet.
Additionally, participants will be asked to participate in cognitive behavioral therapy (CBT) sessions once weekly (from Weeks 1 through 12) on a non-infusion day.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
San Leandro, California, Förenta staterna, 94578
- Alameda Health System
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- Interdisciplinary Substance Use and Brain Injury Facility
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Addiction Institute of Mount Sinai
-
-
South Carolina
-
Greenville, South Carolina, Förenta staterna, 29617
- Prisma Health
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75247
- UT Southwestern Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria
Study participants must:
- Be 18 to 65 years old
- Be able to sufficiently understand, speak, and read English
- Be interested in reducing or stopping methamphetamine use
- Meet criteria for methamphetamine use disorder
- Use acceptable methods of contraception during participation in the study
Exclusion criteria
Study participants must not:
- Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
- Be currently in jail, prison, or inpatient overnight facility as required by court of law
- Have upcoming surgery planned or scheduled
- Be currently pregnant, breastfeeding, or planning on conception, if biologically female
Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Ketamine
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks. |
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
Andra namn:
|
|
Aktiv komparator: Midazolam
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks. |
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Treatment Response
Tidsram: 2 weeks
|
Defined as having at least three methamphetamine-negative urine samples out of four samples obtained during Weeks 3 and 4. |
2 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Non-serious adverse outcomes associated with IV ketamine treatment for methamphetamine use
Tidsram: 6 weeks
|
Defined by non-serious adverse events (associated with the IV ketamine treatment) reported during the study intervention phase (weeks 1 to 6). Participants will be assessed for adverse events at each study visit. |
6 weeks
|
|
Adherence to treatment
Tidsram: 6 weeks
|
Defined by completion of at least five out of eight IV ketamine or IV midazolam infusions. |
6 weeks
|
|
Total abstinence
Tidsram: 2 weeks
|
Defined as four out of four methamphetamine-negative urine samples obtained during Weeks 3 and 4 (since missing urine drug screens will be counted as positive). |
2 weeks
|
|
Abstinence from methamphetamine use
Tidsram: 12 weeks
|
Defined by the self-reported days of methamphetamine use as reported on the Timeline Followback (TLFB) from Week 1 to Week 4, Week 5 to Week 6, and Week 7 to Week 12. |
12 weeks
|
|
Differences in methamphetamine-negative urine samples from Weeks 1 to 6 and between ketamine and midazolam arms.
Tidsram: 6 weeks
|
Urine samples will be collected twice a week at in-person visits. |
6 weeks
|
|
Differences in methamphetamine-negative urine samples from Weeks 1 and 2 versus Weeks 3 and 4.
Tidsram: 4 weeks
|
Urine samples will be collected twice a week at in-person visits. |
4 weeks
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Madhukar Trivedi, MD, Professor (Tenured)
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Kemiskt inducerade störningar
- Substansrelaterade störningar
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Kolväten
- Cyklohexaner
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Benzazepiner
- Bensodiazepiner
- Midazolam
- Ketamin
Andra studie-ID-nummer
- STU-2023-1086
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .